DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
- New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale
- Integrated AI models and workflows support better informed decisions about which antibodies to progress experimentally
London, UK – 1 October 2026 – DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform.
The platform brings together antibody design, structure prediction and validation tools within a single workflow.
